The small molecules in question are ASTX029, an ERK1/2 inhibitor that has completed a phase 2 study, and ASTX295 an MDM2 antagonist that has undergone a phase 1 trial. Both candidates have ...

Western blot assays were performed to identify the presence of p53, phospho-p53, and murine double minute 2 (MDM2) isoforms in plasma samples. Densitometric analysis was used to determine the ...

In oncology, she highlighted MDM2-p53 antagonist brigimadlin, which has advanced into a pivotal trial for dedifferentiated liposarcoma, a rare cancer with limited treatment options so far ...

Background Fibrolamellar carcinoma (FLC), a rare and fatal liver cancer lacking effective drug therapy, is driven by the DNAJ-PKAc fusion oncoprotein. However, the underlying mechanism of DNAJ-PKAc’s ...

In the published article, there was an error in the legend for Figures 2, 3 as published. The legends for Figures 2, 3 were placed in the wrong order. The legend for ...

1 State Key Laboratory of Component-based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China 2 Haihe Laboratory of Modern Chinese Medicine, Tianjin University of ...

Search for other works by this author on: ...

Washington University in St. Louis, Saint Louis, MO.

Chemistry Department, School of Life Sciences, University of Sussex, Brighton BN1 9QJ, U.K. Bio-Techne (Tocris), The Watkins Building, Atlantic Road, Avonmouth ...